Ann: Release of Shares from Voluntary Escrow, page-17

Congrats to DickyB on this post and analysis , regarding the Release of these Escrowed shares .
I was going to ask DickyB from where this information was extracted ,,,but I decided to try to have a look to see if I could source it .
Certainly ....I am not sure if this is correct ....but it seems to have been one of the Resolutions Voted on , in an Extraordinary General Meeting voted on on the 6th August 2021 .

The regular and terrific posters who intimately know the significance of this , might be able to add further expansoinary details .

https://company-announcements.copyright link/asx/imu/ad70e8a5-f650-11eb-b760-a6c58728ef41.pdf

Notice ofExtraordinary General Meeting 6^th August 2021

Deferred consideration There deferred consideration is subject to the achievement of certain milestones relating to the development of CF33 as follows: Milestone Description Consideration Shares 1 Allowance of investigational new drug by the US Food and Drug Administration in relation to CF33 119,354,838 Consideration Shares 2 Dosing of first patient in a Phase 1 clinical trial for CF33 134,258,064 Consideration Shares 3 Meeting Phase 1 safety endpoints excluding efficacy and dose 149,193,548 Consideration Shares